TY - JOUR
T1 - Rituximab-including combined modality treatment for primary thyroid lymphoma
T2 - An effective regimen for elderly patients
AU - Watanabe, Natsuko
AU - Narimatsu, Hiroto
AU - Noh, Jaeduk Yoshimura
AU - Kunii, Yo
AU - Mukasa, Koji
AU - Matsumoto, Masako
AU - Suzuki, Miho
AU - Sekiya, Kenichi
AU - Ohye, Hidemi
AU - Yoshihara, Ai
AU - Iwaku, Kenji
AU - Kobayashi, Sachiko
AU - Kameyama, Kaori
AU - Kobayashi, Kazuhiko
AU - Nishikawa, Yoshitaka
AU - Kami, Masahiro
AU - Sugino, Kiminori
AU - Ito, Koichi
PY - 2014/6/1
Y1 - 2014/6/1
N2 - Background: Primary thyroid lymphoma (PTL) develops mostly in middle-aged and older females. However, the optimal treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL), which accounts for most PTL cases, is unclear. Rituximab is a promising drug that, in combination with traditional combination therapy, has demonstrated an increased antitumor effect without a substantial increase in toxicity. In this study, treatment outcomes of elderly patients with thyroid DLBCL who underwent rituximab-including combination therapy were analyzed. Method: Between January 2005 and December 2011, 43 patients 60 years of age or older (median 71 years, range 60-80 years) were diagnosed as having stage IE (n = 12) or stage IIE (n = 31) DLBCL, and three courses of R-CHOP therapy (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, adriamycin 40 mg/m2, vincristine 1.4 mg/m 2, and prednisolone 100 mg/body) and involved field irradiation were planned. Treatment outcomes of these patients were retrospectively reviewed. Results: Two patients terminated the treatment because of interstitial pneumonia during R-CHOP therapy. Only one patient showed treatment resistance and the regimen was changed; 42 patients (98%) responded to the treatment. Five-year overall survival and event-free survival were 87% (95% confidence interval [95% CI], 64-96%) and 74% (95% CI, 50-89%), respectively. Conclusion: The results of the present study indicate that rituximab-including combination therapy was effective for elderly patients with thyroid DLBCL. A multicenter, long-term observational study is needed to confirm this, and additional refinement of the treatment protocol is required to optimize the antitumor effect.
AB - Background: Primary thyroid lymphoma (PTL) develops mostly in middle-aged and older females. However, the optimal treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL), which accounts for most PTL cases, is unclear. Rituximab is a promising drug that, in combination with traditional combination therapy, has demonstrated an increased antitumor effect without a substantial increase in toxicity. In this study, treatment outcomes of elderly patients with thyroid DLBCL who underwent rituximab-including combination therapy were analyzed. Method: Between January 2005 and December 2011, 43 patients 60 years of age or older (median 71 years, range 60-80 years) were diagnosed as having stage IE (n = 12) or stage IIE (n = 31) DLBCL, and three courses of R-CHOP therapy (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, adriamycin 40 mg/m2, vincristine 1.4 mg/m 2, and prednisolone 100 mg/body) and involved field irradiation were planned. Treatment outcomes of these patients were retrospectively reviewed. Results: Two patients terminated the treatment because of interstitial pneumonia during R-CHOP therapy. Only one patient showed treatment resistance and the regimen was changed; 42 patients (98%) responded to the treatment. Five-year overall survival and event-free survival were 87% (95% confidence interval [95% CI], 64-96%) and 74% (95% CI, 50-89%), respectively. Conclusion: The results of the present study indicate that rituximab-including combination therapy was effective for elderly patients with thyroid DLBCL. A multicenter, long-term observational study is needed to confirm this, and additional refinement of the treatment protocol is required to optimize the antitumor effect.
UR - http://www.scopus.com/inward/record.url?scp=84902193323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902193323&partnerID=8YFLogxK
U2 - 10.1089/thy.2013.0523
DO - 10.1089/thy.2013.0523
M3 - Article
C2 - 24547778
AN - SCOPUS:84902193323
SN - 1050-7256
VL - 24
SP - 994
EP - 999
JO - Thyroid
JF - Thyroid
IS - 6
ER -
